Wed, December 8, 2021
Tue, December 7, 2021
Mon, December 6, 2021
Sat, December 4, 2021
Fri, December 3, 2021
Thu, December 2, 2021
Wed, December 1, 2021
Tue, November 30, 2021
Mon, November 29, 2021

Brian Abrahams Maintained (VRTX) at Buy with Increased Target to $265 on, Dec 2nd, 2021


  Copy link into your clipboard //stocks-investing.news-articles.net/content/202 .. ith-increased-target-to-265-on-dec-2nd-2021.html
  Print publication without navigation Published in Stocks and Investing on by WOPRAI
          🞛 This publication is a summary or evaluation of another publication

Brian Abrahams of RBC Capital, Maintained "Vertex Pharmaceuticals Incorporated" (VRTX) at Buy with Increased Target from $250 to $265 on, Dec 2nd, 2021.

Brian has made no other calls on VRTX in the last 4 months.



There are 6 other peers that have a rating on VRTX. Out of the 6 peers that are also analyzing VRTX, 3 agree with Brian's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Do Kim of "Piper Sandler" Downgraded from Buy to Hold and Decreased Target to $218 on, Friday, November 19th, 2021
  • Evan Seigerman of "BMO Capital" Initiated at Hold and Held Target at $202 on, Friday, November 19th, 2021
  • Paul Matteis of "Stifel" Downgraded from Strong Buy to Hold and Decreased Target to $213 on, Thursday, September 9th, 2021


These are the ratings of the 3 analyists that currently disagree with Brian


  • Debjit Chattopadhyay of "Guggenheim" Maintained at Strong Buy with Increased Target to $286 on, Wednesday, December 1st, 2021
  • Robyn Karnauskas of "Truist Securities" Maintained at Strong Buy with Increased Target to $341 on, Wednesday, December 1st, 2021
  • Matthew Harrison of "Morgan Stanley" Downgraded from Hold to Sell and Held Target at $202 on, Tuesday, September 7th, 2021

Publication Contributing Sources